Stay updated on Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial
Sign up to get notified when there's something new on the Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial page.

Latest updates to the Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. This is a minor version update with no impact on study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded a dedicated Locations section with regional site listings (Arizona, California, Florida, Tennessee, Texas, Alberta, and Quebec) and replaced the previous location blocks. The HHS Vulnerability Disclosure link was removed in this update.SummaryDifference0.8%

- Check45 days agoChange DetectedRevision: v3.3.2 was implemented, replacing the previous v3.3.1. This is a minor maintenance update that does not modify any study details, eligibility criteria, or results displayed on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check53 days agoChange DetectedThe Publications section text was updated from 'about the study results' to 'about the results of the study,' and a new 'Revision: v3.3.1' label was added.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page no longer shows a government funding status notice. This administrative banner did not affect study details or results.SummaryDifference0.3%

- Check74 days agoChange DetectedNo significant changes to core study details were detected; only minor textual or formatting edits appear in the screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial page.